3+ hour, 2+ min ago   (131+ words) TradingView Roivant Sciences Announces FDA Approval and U.S. Availability of LISRAYA for Dermatomyositis Roivant Sciences announced FDA approval of LISRAYA (brepocitinib) for adults with dermatomyositis and immediate U.S. availability. - FDA approved LISRAYA 30 mg (brepocitinib) for adults with dermatomyositis; product available immediately in…...

5+ hour, 40+ min ago   (330+ words) For women, the skin can sometimes become an early visible reflection of an unhealthy lifestyle For women, the skin can sometimes become an early visible reflection of an unhealthy lifestyle. Acne, pigmentation, dullness, excessive oiliness, dryness, sensitivity and recurrent rashes…...

5+ hour, 30+ min ago   (405+ words) The National Law Review The National Law Review uses cookies to track usage trends and patterns to better understand and improve our website. By using this website and/or clicking on any link on the website, you confirm your consent…...

8+ hour, 24+ min ago   (327+ words) Having established the effectiveness of her nanoparticle drug-delivery system for cancer immunotherapy, University of Massachusetts Amherst researcher Prabhani Atukorale, has been awarded $2.5 million from the National Institutes of Health to broaden the scope of her vaccine research to include treating…...

11+ hour, 3+ min ago   (578+ words) Keytruda® (pembrolizumab) is Merck’s blockbuster monoclonal antibody drug, designed to restore the immune system’s anti-cancer response. Intismeran autogene, developed by Moderna, is a personalized, mRNA-based cancer vaccine that encourages the immune system to target tumor mutations. The combination of pembrolizumab…...

1+ day, 2+ hour ago   (221+ words) CMS has proposed cutting dermatology reimbursement by 11% in Year 1, escalating to an estimated 15–18% annually under the CY 2027 Fee Schedule. These unprecedented reductions stem from two deeply flawed policies: gutting reimbursement for specialty-specific practice expenses and slashing payments for same-day procedures....

1+ day, 6+ hour ago   (519+ words) Philadelphia’s BriaCell Hits Key Milestone in Its Off-the-Shelf Melanoma Vaccine Program BioBuzz Philadelphia’s BriaCell Hits Key Milestone in Its Off-the-Shelf Melanoma Vaccine Program BriaCell Therapeutics, which maintains a U.S. office on Arch Street in Philadelphia alongside its Canadian corporate office…...

1+ day, 6+ hour ago   (689+ words) Docwire News Upadacitinib Shows Promising Efficacy for Alopecia Areata According to phase 3 data, upadacitinib may represent a potential treatment option for patients with severe alopecia areata. There is currently an unmet need for systemic therapies for alopecia areata—with only…...

1+ day, 5+ hour ago   (147+ words) Acne may be one of the most common conditions seen in dermatology clinics, but its long-term consequences should not be underestimated. He cautioned against the growing influence of social media–driven skincare, noting that viral routines, excessive product layering and…...

1+ day, 1+ hour ago   (93+ words) Brepocitinib improved skin-specific symptoms of dermatomyositis, according to an analysis of the phase 3 VALOR trial published in JAMA Dermatology. These findings, which included rapid and durable reductions in itch and skin disease activity, come after the release of the primary…...